Anthem Bioscienc

Which are the latest news on Anthem Bioscienc?

Why is Anthem Biosciences Ltd falling/rising?

As of 05-Sep, Anthem Biosciences Ltd's stock is experiencing a decline of 1.65% after a trend reversal, despite a strong year-to-date performance of 43.45%. The recent drop is attributed to decreased investor participation and volatility during the trading session.

As of 05-Sep, Anthem Biosciences Ltd's stock price is currently falling, with a change of -15.65, representing a decline of 1.65%. This decrease follows a trend reversal after three consecutive days of gains. Although the stock opened with a gain of 2% and reached an intraday high of Rs 970.8, it ultimately fell to a day's low of Rs 926.8, indicating volatility within the trading session.<BR><BR>Despite the recent price drop, the stock has shown strong performance over longer periods, with a year-to-date increase of 43.45% compared to a decline in the benchmark Sensex of 10.21%. However, today's performance underperformed the sector by 1.61%, and there has been a notable decrease in investor participation, with delivery volume falling by 37.78% against the 5-day average. <BR><BR>Additionally, while the stock is trading above its moving averages, the overall sentiment appears to be affected by the recent decline in trading volume and the trend reversal, contributing to the current price drop.

What does Anthem Bioscienc do?

Anthem Biosciences Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 418 Cr and a net profit of 120 Cr for June 2026. It has a market cap of INR 50,802 Cr, a P/E ratio of 85.00, and a return on equity of 20.02%.

Overview: <BR>Anthem Biosciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Mid Cap company.<BR><BR>History: <BR>Anthem Biosciences Ltd was originally incorporated as "Anthem Biosciences Private Limited" in 2006. The company transitioned from a Private to a Public Company and changed its name to "Anthem Biosciences Limited," with the conversion certificate issued on December 10, 2024. The most recent quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 418 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 120 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 50,802 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 85.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.22% <BR>Debt Equity: -0.29 <BR>Return on Equity: 20.02% <BR>Price to Book: 16.66 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Anthem Bioscienc?

Anthem Bioscienc's peers include Aurobindo Pharma, Glenmark Pharma, Biocon, Alkem Lab, Abbott India, Glaxosmi. Pharma, Ipca Labs, Gland Pharma, Ajanta Pharma, and Emcure Pharma. Anthem Bioscienc shows excellent growth with a 1-year return of 8.91%, while Aurobindo Pharma leads with 64.44% and Abbott India lags at -17.91%.

Peers: The peers of Anthem Bioscienc are Aurobindo Pharma, Glenmark Pharma, Biocon, Alkem Lab, Abbott India, Glaxosmi. Pharma, Ipca Labs, Gland Pharma, Ajanta Pharma, and Emcure Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Glaxosmi. Pharma, and Ajanta Pharma, while Good management risk is found at Glenmark Pharma, Anthem Bioscienc, Ipca Labs, Gland Pharma, and Emcure Pharma. Average management risk is present at Aurobindo Pharma and Biocon, while Alkem Lab has Good growth but Average management risk. Below Average growth is noted at Aurobindo Pharma, Biocon, Alkem Lab, and the rest, while Anthem Bioscienc shows Excellent growth. Capital Structure is Excellent for Aurobindo Pharma, Alkem Lab, Abbott India, Glaxosmi. Pharma, Ipca Labs, Gland Pharma, Ajanta Pharma, and the rest, while Biocon has Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aurobindo Pharma at 64.44%, while Abbott India has the lowest at -17.91%. Anthem Bioscienc's 1-year return of 8.91% is higher than Abbott India's but lower than Aurobindo Pharma's. Additionally, Abbott India and Alkem Lab have negative six-month returns.

How big is Anthem Bioscienc?

As of 31st August, Anthem Biosciences Ltd has a market capitalization of 50,802.00 Cr, with net sales of 2002.34 Cr and a net profit of 575.95 Cr for the latest four quarters.

As of 31st August, Anthem Biosciences Ltd has a market capitalization of 50,802.00 Cr, categorizing it as a Mid Cap company.<BR><BR>For the latest four quarters, the company reported net sales of 2002.34 Cr and a net profit of 575.95 Cr.<BR><BR>As of the latest annual period in March 2026, the shareholder's funds amounted to 3,042.52 Cr, while total assets were reported at 3,401.97 Cr.

Are Anthem Biosciences Ltd latest results good or bad?

Anthem Biosciences Ltd's latest results are concerning, showing a 31.54% sequential revenue decline to ₹418.22 crores and a 36.79% drop in net profit to ₹119.94 crores, indicating significant operational challenges and raising questions about the company's growth sustainability.

Anthem Biosciences Ltd's latest results are concerning, reflecting a significant downturn in performance. In the quarter ending June 2026, the company experienced a sharp revenue decline of 31.54% sequentially, with net sales dropping to ₹418.22 crores from ₹610.94 crores in the previous quarter. This marks the lowest quarterly revenue the company has seen in recent times and represents a 22.58% decline year-on-year.<BR><BR>The operating profit also took a hit, decreasing by 43.64% to ₹150.57 crores, leading to a compression in operating margins from 43.74% to 36.0%. Additionally, net profit fell by 36.79% quarter-on-quarter to ₹119.94 crores, indicating a challenging operational environment.<BR><BR>Overall, the results suggest that Anthem Biosciences is facing significant operational challenges, raising questions about its growth sustainability and the factors contributing to this sharp contraction. The company’s performance in this quarter is classified as a setback, contrasting sharply with its previous strong showing.

Should I buy, sell or hold Anthem Biosciences Ltd?

When is the next results date for Anthem Biosciences Ltd?

Anthem Biosciences Ltd will announce its results on July 21, 2026.

Anthem Biosciences Ltd is scheduled to declare its results on July 21, 2026.

Has Anthem Biosciences Ltd declared dividend?

Yes, Anthem Biosciences Ltd has declared a 100% dividend, with an ex-date of June 25, 2026. However, the company has shown no price or dividend returns over the longer periods, indicating a need for performance improvement.

Anthem Biosciences Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>Percentage announced: 100%<BR>Ex-date: 25 Jun 26<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, Anthem Biosciences Ltd achieved a price return of 13.0%, a dividend return of 0.29%, resulting in a total return of 13.29%.<BR><BR>Over the past 6 months, the company recorded a price return of 21.11%, a dividend return of 0.32%, leading to a total return of 21.43%.<BR><BR>For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 2-year period, the company saw no price return or dividend return, culminating in a total return of 0.0%.<BR><BR>Over the last 3 years, there were no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Finally, in the 5-year period, there were no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>Overall, while Anthem Biosciences Ltd has declared a significant dividend, the total returns over the longer periods indicate a lack of growth in price and dividends, suggesting a need for improvement in performance.

How has been the historical performance of Anthem Bioscienc?

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

Answer:<BR>The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

Is Anthem Bioscienc overvalued or undervalued?

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.<BR><BR>In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.